Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New sensor could help doctors drain fluid from heart failure Patients' lungs

NCT ID NCT07600398

Disease control Sponsor: Instituto Cardiovascular de Buenos Aires Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a wearable sensor that measures lung fluid can help doctors better treat fluid buildup in patients hospitalized for acute heart failure. About 216 adults will be randomly assigned to either standard care or care guided by the sensor. The goal is to see if the sensor-guided approach reduces the risk of death, rehospitalization, or urgent heart failure visits within 30 days after discharge.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remote Dielectric Sensing (ReDS) device
What this could lead to
If it works, this could give doctors a simple, non-invasive tool to better manage fluid levels in heart failure patients, potentially reducing hospital readmissions.
What could go wrong
This is a relatively small, early-stage trial (216 participants) testing a device, not a drug. The benefit may be modest or not statistically significant, and results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 216 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥21 years * Hospitalization for acute heart failure with signs of congestion within 48 hours of admission * Elevated natriuretic peptides (NT-proBNP \>1000 pg/mL or BNP equivalent) * Ability to provide informed consent Exclusion Criteria: * Need for inotropes, vasopressors, or mechanical circulatory support at enrollment Heart transplant recipient Mechanical ventilation at enrollment Conditions that prevent reliable ReDS measurement Planned cardiac surgery or intervention during the study period Severe renal dysfunction (eGFR \<15 mL/min/1.73 m² or dialysis) Life expectancy \<3 months Inability to complete follow-up Participation in another interventional trial Any condition that may compromise safety or study integrity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure (AHF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure (AHF)

Contacts and locations

Locations

  • Instituto Cardiovascular de Buenos Aires

    Buenos Aires, Buenos Aires, 1428, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.